Skip to main content

IBA Launches versatile high-energy new Cyclotron

-

Thursday, June 10, 2021 - 10:40

<p>&nbsp;</p> <p><em>IBA leverages 35 years of experience and innovation in the new Cyclone<sup>®</sup> IKON with enhanced availability of theranostic radiopharmaceuticals and reduced radiopharmacy footprint<br /> &nbsp;</em><br /> <strong>Louvain-la-Neuve, Belgium, &nbsp;10 June 2021</strong> -&nbsp; <span>IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today launches its new high energy and high-capacity cyclotron, the Cyclone</span><em><sup>®</sup></em><span> IKON, which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV. The Cyclone</span><em><sup>®</sup></em><span> IKON was showcased during a virtual live event and the replay can be watched <a href="https://youtu.be/LQsNCZcuwG8">here</a>.</span></p> <p><span>Currently, there are still a large number of patients for whom cancer treatment fails, despite major scientific advances. Nuclear medicine is emerging as a relevant modality to address this gap by extending overall survival and quality of life for cancer patients. Theranostics and targeted therapies allow the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. The growing number of clinical trials (200+) and ongoing increase of new radiotherapeutic molecule developments support the great potential of radioligand therapy. &nbsp;</span></p> <p><span>“To enable this revolution, we must enhance the availability of novel isotopes and boost their production capacity. In its role, the cyclotron must be a reliable and sustainable production source of isotopes for the radiopharmaceutical industry and this is particularly the case for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64, for which the demand has been consistently expanding year after year.”<strong> Bruno Scutnaire, Vice-President of IBA's RadioPharma Solutions Division commented.</strong></span></p> <p><span>To address these new market needs, IBA has redesigned its previous model, Cyclone</span><em><sup>®</sup></em><span> 30 MeV, and created a next generation system, the Cyclone</span><em><sup>®</sup></em><span> IKON. It is more compact and versatile than ever and is capable of working over a large energy span (13 to 30MeV) with full current capacity to enable the large-scale and high-purity production of emerging PET, SPECT and “parent” isotopes.&nbsp;</span></p> <p><span>The first two units of the Cyclone</span><em><sup>®</sup></em><span> IKON have already been acquired by two leading companies in radiopharmaceuticals production: The Institute of Radioelements (IRE) in Belgium and Curium Pharma in St Louis, USA. Commissioning is scheduled for 2023.</span></p> <p><span><strong>Renaud Dehareng, CEO of Curium Pharma said: </strong>“IBA has been a trusted partner of Curium for a long time. We selected IBA for its globally recognized expertise and due to the outstanding capabilities and reliability of the Cyclotron.”</span></p> <p><span>We selected IBA because of the reliability of its equipment. It has the most compact and efficient high energy cyclotron on the market." <strong>said Erich Kollegger, CEO of IRE.</strong></span><br /> &nbsp;</p> <p>&nbsp;</p> Read full press release  
Share

news.more_news_title

IBA et SCK CEN lancent Pantera

IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

Louvain-La-Neuve, Belgium, 22 September 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN today announced the name of their joint-venture: Pantera SA/NV, which they believe will bring new hope for cancer patients. As indicated in the announcement of the R&amp;D strategic partnership, this new company will aim to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, Pantera’s ultimate goal is to improve the accessibility of a future innovative cancer therapy based on 225Ac. &nbsp; The complementarity of IBA and SCK CEN’s expertise has been demonstrated by the extensive and comprehensive R&amp;D work that has been conducted during the last year as they work towards being able to produce large volumes of 225Ac. Pantera is now completing the technical feasibility studies before working on the final design and construction of its first facility in Mol, Belgium. Groundbreaking is expected to take place in 2024, with production starting in 2027. &nbsp; Sven Van den Berghe, former Director of the Nuclear Materials Science Institute at SCK CEN, has been appointed as Chief Executive Officer, and Samy Bertrand, former technical leader for theranostics applications at IBA, takes the position of Chief Technical Officer. &nbsp; Bruno Scutnaire, President of IBA RadioPharma Solutions and Chairman of the Board of Directors of Pantera, said: “Actinium-225 offers great promise for the treatment of a large variety of cancers, but only very little of the material is available worldwide today.&nbsp; Once cancer treatments based on 225Ac receive approval, Pantera will focus on enabling access to a dependable supply of this promising isotope.” &nbsp; Peter Baeten, Deputy Director-General of SCK CEN and Board member of Pantera, commented: “Launching Pantera was a logical choice for SCK CEN and IBA, allowing the joint-venture to leverage the innovative capabilities of both organizations, whilst utilizing the speed of an autonomous startup necessary in this fast-evolving field.” &nbsp; Sven Van den Berghe, appointed Chief Executive Officer of Pantera, added: “I am excited about the opportunity to help advance the mission of Pantera to bring a new hope for cancer patients by enabling the widespread use of radioisotopes, such as actinium-225, as a basis for promising new radiopharmaceuticals. Pantera offers ’A better fight for life’, potentially bringing an effective and efficient treatment option while maximizing the quality of life of the patients, with the possibility to expand the production to other isotopes in the future.” &nbsp; Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer. &nbsp;
Читать далее
Jiming Cai, General Manager of CNRT; Chen Li,  IBA Radio Pharma Solutions Sales VP China

CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in China

The Cyclone® IKON is IBA’s new high energy and high-capacity cyclotron which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, August 30, 2022 –IBA(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announced it has signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million. The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. Jiming Cai, General Manager of CNRT, commented: “We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first Cyclone® IKON cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.” &nbsp; Bruno Scutnaire, President of IBA RadioPharma Solutions, added: “There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.” &nbsp; About CNRT Chengdu New Radiomedicine Technology Co., Ltd. was established in the year 2016. It is a high-tech enterprise integrating Research and development of radiopharmaceuticals, innovation and industrialization, engaged in research, production and sales of medical isotopes, carry out demonstration research on the diagnosis and treatment of a variety of malignant tumor diseases, provide nuclear medicine technical services and scientific and technological consulting, etc. The company has built up an advanced radiopharmaceutical testing and research platform, an advanced radioactive pharmacology research platform, and an advanced radiopharmaceutical industrialization innovation platform. CNRT will ensure continuously provide high-quality, High efficiency and affordable radioactive diagnosis and treatment drugs for the patients, provide high-quality medical isotope nuclide products for the radiopharmaceutical industry, through technology, concept and products innovation. About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com &nbsp; CONTACTS Soumya Chandramouli Chief Financial Officer +32 10 475 890 Investorrelations@iba-group.com &nbsp; Olivier Lechien Corporate Communication Director +32 10 475 890 communication@iba-group.com &nbsp; Consilium Strategic Communications Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
Читать далее